Drug Profile

NSHO 101

Alternative Names: EA-1080; NSHO-101

Latest Information Update: 05 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EA Pharma
Developer EA Pharma; Ensho Therapeutics
Class Anti-inflammatories; Small molecules
Mechanism of Action Integrin alpha4beta7 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

05 Mar 2025 Pharmacodynamics data from a phase I trial in Inflammatory bowel diseases released by Ensho Therapeutics
14 Feb 2025 Ensho Therapeutics plans a phase II trial in Ulcerative colitis (PO), in the first half of 2025
15 Oct 2024 Phase-I clinical trials in Crohn's disease (PO), prior to October 2024 (Ensho therapeutics pipeline, October 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com